Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 2, 2009, Pages 71-93

  Ansquer, Jean Claude ^a   Corda, Christophe ^a   Le Malicot, Karine ^a   Jessent, Valerie ^a  

^a Laboratoires Fournier SA   (France)

Author keywords

atorvastatin; fenofibrate; LDL profile; small dense LDL particles

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

EID: 65549170433     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.03.002     Document Type: Article

References (49)

1. Lindgren F.T., Jensen L.C., Wills R.D., and Freeman N.K. Flotation rates, molecular weights and hydrated densities of the low-density lipoproteins. Lipids 4 (1969) 337-344
2. Krauss R.M., and Burke D.J. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res. 23 (1982) 97-104
3. Swinkels D.W., Hak-Lemmers H.L., and Demacker P.N. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low-density lipoprotein subfractions. J Lipid Res. 28 (1987) 1233-1239
4. Chapman M.J., Laplaud P.M., Luc G., et al. Further resolution of the low-density lipoprotein spectrum in normal human plasma: Physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 29 (1988) 442-458
5. McNamara J.R., Campos H., Ordovas J.M., et al. Effect of gender, age, and lipid status on low-density lipoprotein subfraction distribution. Results from the Framingham Offspring Study. Arteriosclerosis 7 (1987) 483-490
6. Campos H., Blijlevens E., McNamara J.R., et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 12 (1992) 1410-1419
7. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
8. Campos H., Genest Jr. J.J., Blijlevens E., et al. Low-density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 12 (1992) 187-195
9. Griffin B.A., Freeman D.J., Tait G.W., et al. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106 (1994) 241-253
10. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276 (1996) 882-888
11. Gardner C.D., Fortmann S.P., and Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
12. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 95 (1997) 69-75
13. Feingold K.R., Grunfeld C., Pang M., et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 12 (1992) 1496-1502
14. Austin M.A. Low-density lipoprotein subclass phenotypes and familial combined hyperlipidemia. Diabetes Metab Rev. 7 (1991) 173-177
15. Hunt S.C., Wu L.L., Hopkins P.N., et al. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension. Arteriosclerosis 9 (1989) 335-344
16. Dejager S., Bruckert E., and Chapman M.J. Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyper lipidemia. J Lipid Res. 34 (1993) 295-308
17. Swinkels D.W., Demacker P.N., Hendriks J.C., and van't Laar A. Low-density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals [publish ed correction appears in Arteriosclerosis. 1990;10:491]. Arteriosclerosis 9 (1989) 604-613
18. Coresh J., Kwiterovich Jr. P.O., Smith H.H., and Bachorik P.S. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 34 (1993) 1687-1697
19. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-Year follow-up data from the Québec Cardiovascular Study. Art erioscler Thromb Vase Biol. 25 (2005) 553-559
20. Lamarche B., St-Pierre A.C., Ruel I.L., et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 17 (2001) 859-865
21. St-Pierre A.C., Ruel I.L., Cantin B., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104 (2001) 2295-2299
22. Campos H., Moye L.A., Glasser S.P., et al. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 286 (2001) 1468-1474
23. Newcombe R.G. Interval estimation for the difference between independent proportions: Comparison of eleven methods [published correction appears in Stat Med. 1999;18:1293]. Stat Med. 17 (1998) 873-890
24. Packard C.J., and Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 17 (1997) 3542-3556
25. Feher M.D., Caslake M., Foxton J., et al. Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate. Diabetes Metab Res Rev. 15 (1999) 395-399
26. Rizzo M., and Berneis K. The clinical relevance of low-density lipoproteins size modulation by statins. Cardiovasc Drugs Ther. 20 (2006) 205-217
27. Nawrocki J.W., Weiss S.R., Davidson M.H., et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arter ioscler Thromb Vasc Biol. 15 (1995) 678-682
28. Ooi T.C., Heinonen T., Alaupovic P., et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 17 (1997) 1793-1799
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
30. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed February 23, 2009
31. World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site] (1989), WMA, Ferney-Voltaire, France. http://www.wma.net Accessed February 23, 2009
32. Luc G., Bard J.M., Ferrières J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I and lipoprotein A-I/A-II in prediction of coronary heart disease: The PRIME Study (Prospective Epidemiological Study of Myocardial Infarction). Arterioscler Thromb Vasc Biol. 22 (2002) 1155-1161
33. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18 (1972) 499-502
34. Sniderman A.D. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol. 90 (2002) 48i-54i
35. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
36. Guérin M., Bruckert E., Dolphin P.J., et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 16 (1996) 763-772
37. Guerin M., Lassel T.S., Le Goff W., et al. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
38. Winkler K., Weltzien P., Friedrich I., et al. Qualitative effect of fenofibrate and quantitative effect for atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin Endocrinol Diabetes 112 (2004) 241-247
39. US Food and Drug Administration. Medical Dictionary for Regulatory Activities [MedDRA Web site] [formerly COSTART]. http://www.meddramsso.com/MSSOWeb/index.htm Accessed January 12, 2009.
40. Frost R.J., Otto C., Geiss H.C., et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87 (2001) 44-48
41. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
42. Vakkilainen J., Steiner G., Ansquer J.C., et al., the DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737
43. Steiner G., Otvos J., Vakkilainen J., et al. Fenofibrate and lipoprotein size in type 2 diabetes, evaluated by NMR and comparison to gradient gel electrophoresis (GGE) determinations. Diabetologia 46 (2003) A74 Abstract
44. Lemieux I., Salomon H., and Després J.P. Contribution of apo Oil reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Ann Med 35 (2003) 442-448
45. Lemieux I., Laperrière L., Dzavik V., et al. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162 (2002) 363-371
46. El Harchaoui K., van der Steeg W.A., Stroes E.S., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 49 (2007) 547-553
47. Karalis D.G., Ishisaka D.Y., Luo D., et al. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol 100 (2007) 445-449
48. Williams K., Sniderman A.D., Sattar N., et al. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 108 (2003) 2312-2316
49. Scott R, O'Brien R, Fulcher G, et al, for the FIELD Study Investigators. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: The FIELD study [online publication ahead of print November 4, 2008]. Diabetes Care.